Focus: Oncoinvent is a Norwegian radiopharmaceutical company focused on oncology and neurology applications, operating as a public company since 2010. The company specializes in targeted radiotherapy solutions for difficult-to-treat cancers.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Oncoinvent to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Oncoinvent
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Oncoinvent's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Oncoinvent ASA: Minutes from Annual General Meeting - Finansavisen
Oncoinvent ASA: Minutes from Annual General Meeting Finansavisen
Oncoinvent Publishes 2025 Annual Report as Radspherin Program Advances - The Globe and Mail
Oncoinvent Publishes 2025 Annual Report as Radspherin Program Advances The Globe and Mail
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
First experience with intraperitoneal (224)Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Targeted alpha therapy of ovarian cancer with (212)Pb-labeled anti-PTK7 antibody: On-site (212)Pb production and preclinical insights.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo